MindImmune Therapeutics

The company's core strategy centers on the discovery that certain peripheral immune cells can infiltrate the brain and contribute to the neuronal damage seen in conditions like Alzheimer's disease. MindImmune's business model is to develop first-in-class biologic therapeutics that modulate the immune system to prevent this neuroinflammatory damage. The company operates through a combination of in-house research, strategic partnerships, and venture funding. Since its inception, MindImmune has raised a total of $13.6M over multiple funding rounds, including a significant $12.4 million Series A financing in June 2022. Key investors include Dolby Family Ventures, Pfizer Ventures, and the Alzheimer's Drug Discovery Foundation.

MindImmune's lead program, MITI-101, is a monoclonal antibody therapeutic in late-stage preclinical development for Alzheimer's disease. This antibody is designed to act in the bloodstream to neutralize CD11c+ innate immune cells, preventing them from being recruited into the brain where they would otherwise cause inflammation and damage synapses. By blocking this immune cell traffic, MITI-101 aims to reduce cognitive symptoms and slow disease progression. The company is advancing MITI-101 toward an Investigational New Drug (IND) filing to initiate human clinical trials. Beyond Alzheimer's, the company is also exploring treatments for other CNS disorders like Huntington's disease and neuropathic pain. Based in Kingston, Rhode Island, MindImmune maintains a strong affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island, leveraging academic resources and talent to advance its drug development programs.